Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

29.65 -0.40 (-1.33%)
Streaming Delayed Price Updated: 11:45 AM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗
This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Where Stoke Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
A Look Ahead: Stoke Therapeutics's Earnings Forecast ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
6 Analysts Have This To Say About Stoke Therapeutics ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Examining the Future: Stoke Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Stoke Therapeutics ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Expectations For Stoke Therapeutics's Future ↗
 
Via Benzinga
News headline image
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals ↗
STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's... 
Via Chartmill
News headline image
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs. 
Via Investor's Business Daily
Topics Earnings
News headline image
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics ↗
 
Via Benzinga
News headline image
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal ↗
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday ↗
 
Via Benzinga
News headline image
STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Going On With Stoke Therapeutics Stock Tuesday? ↗
After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.